Difference between revisions of "Dacarbazine (DTIC)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Irritant chemotherapy" to "Category:Irritant") Tags: mobile edit mobile web edit |
m |
||
| Line 9: | Line 9: | ||
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
*[[Hodgkin lymphoma, nodular lymphocyte-predominant]] | *[[Hodgkin lymphoma, nodular lymphocyte-predominant]] | ||
| + | *[[Liposarcoma]] | ||
*[[Melanoma]] | *[[Melanoma]] | ||
*[[Pheochromocytoma]] | *[[Pheochromocytoma]] | ||
| Line 22: | Line 23: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Generic names:''' dacarbazin, imidazole carboxamide | + | *'''Generic names:''' dacarbazin, DTIC, imidazole carboxamide |
*'''Brand names:''' Bazipar, Cedcozine, Dacarba, Dacarex, Dacin, Dacmed, Darbazine, Dazine, Decarb, Oncodac, Zydac | *'''Brand names:''' Bazipar, Cedcozine, Dacarba, Dacarex, Dacin, Dacmed, Darbazine, Dazine, Decarb, Oncodac, Zydac | ||
| Line 40: | Line 41: | ||
[[Category:Hodgkin lymphoma medications]] | [[Category:Hodgkin lymphoma medications]] | ||
[[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]] | [[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]] | ||
| + | [[Category:Liposarcoma medications]] | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
[[Category:Pheochromocytoma medications]] | [[Category:Pheochromocytoma medications]] | ||
Revision as of 19:24, 3 February 2020
General information
Class/mechanism: Alkylator, purine analog, inhibits DNA synthesis; exact mechanism unclear. Converted to the active alkylating metabolite MTIC.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Liposarcoma
- Melanoma
- Pheochromocytoma
- Soft tissue sarcoma
- Uveal melanoma
Patient drug information
- Dacarbazine (DTIC) patient drug information (Chemocare)[3]
- Dacarbazine (DTIC) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 5/27/1975: Initial FDA approval
Also known as
- Generic names: dacarbazin, DTIC, imidazole carboxamide
- Brand names: Bazipar, Cedcozine, Dacarba, Dacarex, Dacin, Dacmed, Darbazine, Dazine, Decarb, Oncodac, Zydac
References
Categories:
- Drugs
- Intravenous medications
- Irritant
- Alkylating agents
- Triazenes
- DNA synthesis inhibitors
- Antimetabolites
- Purine analogues
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Liposarcoma medications
- Melanoma medications
- Pheochromocytoma medications
- Soft tissue sarcoma medications
- Uveal melanoma medications
- FDA approved in 1975
- WHO Essential Cancer Medicine